Patent US5417695A successfully refreshed from Google Patents.
US4593044A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Injectable solution for the treatment of inflammations
Assignee: Merckle GmbH
•
Filing: 1984-07-31
•
Granted: 1986-06-03
•
Expires: 2004-07-31
Abstract
Abstract The invention relates to the use of naproxen lysinate, ketoprofen lysinate and/or diclofenac lysinate in the form of an injectable solution in the treatment of inflammations and rheumatic disorders, and to injectable solutions containing the anti-inflammatory active compound naproxen, ketoprofen or diclofenac in the form of its lysinate.
Inventors
- 👤 Gunter Metz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:15
CPC Classifications
C; C07; C07C; C07C59/00; C07C59/40; C07C59/76; C07C59/84; A; A61; A61P; A61P29/00; C07C59/58; C07C59/64
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
49 words
An anti-inflammatory injectable solution consisting essentially of an effective amount of an anti-inflammatory active compound selected from the group consisting of naproxen, ketoprofen and diclofenac in the form of its lysinate and a pharmaceutically acceptable diluent, wherein said solution is stable and has a pH in the physiological range.
Claim 2
Dependent Claim
49 words
An anti-inflammatory injectable solution consisting essentially of an effective amount of an anti-inflammatory active compound selected from the group consisting of naproxen, ketoprofen and diclofenac in the form of its lysinate and a pharmaceutically acceptable diluent, wherein said solution is stable and has a pH in the physiological range.
Claim 3
Dependent Claim
18 words
The injection solution of claim 1, comprising 5-25% by weight of ketoprofen in the form of ketoprofen lysinate.
Claim 4
Dependent Claim
18 words
The injection solution of claim 2, comprising 10-15% by weight of ketoprofen in the form of ketoprofen lysinate.
Claim 5
Dependent Claim
18 words
The injection solution of claim 1, comprising 5-25% by weight of naproxen in the form of naproxen lysinate.
Claim 6
Dependent Claim
18 words
The injection solution of claim 4, comprising 10-15% by weight of naproxen in the form of naproxen lysinate.
Claim 7
Dependent Claim
18 words
The injection solution of claim 1, comprising 2-5% by weight of diclofenac in the form of diclofenac lysinate.
Claim 8
Dependent Claim
29 words
The injection solution of claim 1, in the form of an aqueous solution or of an aqueous solvent mixture which further comprises physiologically tolerated solubilizing agents, stabilizers or preservatives.
Claim 9
Dependent Claim
18 words
The injection solution of claim 7, comprising 5-25% by weight of ketoprofen in the form of ketoprofen lysinate.
Claim 10
Dependent Claim
18 words
The injection solution of claim 8, comprising 10-15% by weight of ketoprofen in the form of ketoprofen lysinate.
Claim 11
Dependent Claim
18 words
The injection solution of claim 7, comprising 5-25% by weight of naproxen in the form of neproxen lysinate.
Claim 12
Dependent Claim
18 words
The injection solution of claim 10, comprising 10-15% by weight of naproxen in the form of naproxen lysinate.
Claim 13
Dependent Claim
18 words
The injection solution of claim 7, comprising 2-5% by weight of diclofenac in the form of diclofenac lysinate.
Claim 14
Independent Claim
65 words
A method for the treatment of inflammations and rheumatic disorders which comprises the administration of an anti-inflammatory injectable solution which consists essentially of an effective amount of an anti-inflammatory active compound selected from the group consisting of naproxen, ketoprofen and diclofenac in the form of its lysinate and a pharmaceutically acceptable diluent, wherein said solution is stable and has a pH in the physiological range.
Claim 15
Independent Claim
65 words
A method for the treatment of inflammations and rheumatic disorders which comprises the administration of an anti-inflammatory injectable solution which consists essentially of an effective amount of an anti-inflammatory active compound selected from the group consisting of naproxen, ketoprofen and diclofenac in the form of its lysinate and a pharmaceutically acceptable diluent, wherein said solution is stable and has a pH in the physiological range.
Claim 16
Dependent Claim
11 words
The method of claim 13, wherein said compound is naproxen lysinate.
Claim 17
Dependent Claim
11 words
The method of claim 13, wherein said compound is ketoprofen lysinate.
Claim 18
Dependent Claim
11 words
The method of claim 13 wherein said compound is diclofenac lysinate.
References Cited (Backward Citations)
US2101867A
Cited
US3845210A
Cited
US3876801A
Cited
US3832465A
Cited
US4241086A
Cited
US4486436A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-06-02 | 1989-12-02 | 1990-06-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-06-02 | 1993-12-02 | 1994-06-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-06-02 | 1997-12-02 | 1998-06-03 | $7700.00 | Window Closed / Lapsed |